EGFR and non-small cell lung carcinoma: Approximately 15%-20% of patients in the US will harbor an activating mutation in the epidermal growth factor receptor (EGFR), with incidence up to 50% in some Asian populations.4 The use of targeted treatments for patients whose tumors harbor these mutations has demonstrated significant benefit in recent years in the metastatic NSCLC setting.